Li X, Fan X W, Liu W, Guo L, Li Y, Hu X, Liang X, Ma X P, Yang S E
Department of Internal Medicine III, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Department of International Radiology, Affliliated Tumor Hospital, Xinjiang Medical University, Urumqi, China.
Genet Mol Res. 2015 Mar 30;14(1):2647-53. doi: 10.4238/2015.March.30.25.
The goal of this study was to investigate damaged liver function after chemotherapy in hepatitis B virus (HBV) carriers with non-Hodgkin lymphoma (NHL) and to evaluate risk factors associated with a high risk of damaged liver function. Clinical histories of 134 HBV carriers with NHL who were treated with chemotherapy were obtained and analyzed for the occurrence of damaged liver function and other related high-risk factors. Analysis showed that 76 patients (56.7%) had damaged liver function after chemotherapy: 6 patients (7.9%) had I degree, 17 patients (22.4%) had II degree, 20 patients (26.3%) had III degree, and 33 patients (43.4%) had IV degree damage. After treatment, 18 patients (23.7%) continued to receive chemotherapy according to their original schedule, 39 patients (51.3%) delayed chemotherapy, 16 patients (21.1%) stopped chemotherapy, and 3 patients (3.9%) died. Analysis of a binary multivariate logistic regression model showed that administration of steroids was a high-risk factor for damaged liver function after chemotherapy in NHL patients. The incidence of damaged liver function after chemotherapy is high among HBV carriers with NHL; therefore, administration of steroid chemotherapy is a high-risk factor.
本研究的目的是调查乙型肝炎病毒（HBV）携带者非霍奇金淋巴瘤（NHL）化疗后肝功能损害情况，并评估与肝功能损害高风险相关的危险因素。获取了134例接受化疗的HBV携带者NHL患者的临床病史，并分析肝功能损害及其他相关高危因素的发生情况。分析显示，76例患者（56.7%）化疗后出现肝功能损害：6例患者（7.9%）为I度，17例患者（22.4%）为II度，20例患者（26.3%）为III度，33例患者（43.4%）为IV度损害。治疗后，18例患者（23.7%）继续按原计划接受化疗，39例患者（51.3%）延迟化疗，16例患者（21.1%）停止化疗，3例患者（3.9%）死亡。二元多因素logistic回归模型分析显示，使用类固醇是NHL患者化疗后肝功能损害的高危因素。HBV携带者NHL患者化疗后肝功能损害发生率较高；因此，使用类固醇化疗是一个高危因素。
